Home » Newsletters » BioWorld Science

BioWorld Science

July 5, 2012

View Archived Issues

Research at Allergan yields novel lysophospholipid receptor ligands

ARRY-614 active in phase I trial

Janssen-Cilag withdraws application to extend approval of Velcade

Chelsea Therapeutics receives feedback on resubmitted Northera NDA

Buparlisib administered with trametinib dimethyl sulfoxide in cancer study

Phase I results available for OPB-51602

Team at Roche patents new PDE10A inhibitors

Bristol-Myers Squibb prepares new HIV attachment inhibitors

New KIF11 inhibitors discovered in Japan

U.S. university presents novel inhibitors of PRCP

Novel compounds for bone disorders designed in Japan

Novel bromodomain-containing protein inhibitors synthesized

Salivary interleukins as possible markers of periodontal tissue destruction

Second patient undergoes subretinal transplant in phase I/II trial

NP-2 enkephalin study does not meet primary objective

Apeptico kicks off phase II AP-301 study

FDA approves first over-the-counter HIV test

Enrollment complete in phase IIb trial of tozadenant

Global pediatric studies of long-lasting hemophilia A and B product candidates begin

Recruitment complete in pivotal Ruconest study

Maximum tolerated dose of NKP-1339 determined in first-in-human trial

SB-485232/PLD combination shows acceptable safety in ovarian cancer

Macrocyclic inhibitors for Flaviviridae infections presented

EXPAND trial in advanced gastric cancer does not meet primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...